Showing 2,101 - 2,120 results of 2,133 for search '(( significantly ((better decrease) OR (teer decrease)) ) OR ( significantly small decrease ))', query time: 0.50s Refine Results
  1. 2101

    Thymoquinone loaded nanoemulgel in streptozotocin induced diabetic wound by Urati Anuradha (20306190)

    Published 2024
    “…</p> <p>In diabetic wound animal model nanoemulgel showed significant decreased levels of TNF-α, IL-6, MMP-9 and IL-1β. …”
  2. 2102

    DataSheet1_Profiling of the serum MiRNAome in pediatric egyptian patients with wilms tumor.PDF by Fatma S. Mohamed (19850220)

    Published 2024
    “…In relation to WT clinicopathological features, decreased levels of hsa-miR-2355-3p showed a significant positive correlation with clinical stage (r = 0.6597, p = 0.0006) and WT metastasis (r = 0.439, p = 0.021). …”
  3. 2103

    Table 1_Evaluating the Implementation of fan-beam CT-guided online adaptive re-planning in definitive cervical cancer radiotherapy.docx by Shuai Sun (775057)

    Published 2025
    “…For OARs, the adaptive plan achieved reductions in the dose to the most irradiated 2 cm³ volume (D2cc) for the rectum, bladder, and small intestine (P<0.001). For patients with ovarian conservation, the dose to the 50% volume (D50) and the mean dose of the bilateral ovaries were decreased (P<0.001). …”
  4. 2104

    Data Sheet 2_Effect of thyme-ivy syrup on antiviral immune response in patients with mild COVID-19: a prospective, open-label, randomized pilot study.docx by Stephanie Dauth (13274397)

    Published 2025
    “…Significant between-group differences were observed for changes in some parameters at day 4 (e.g., IL-10) and day 14. …”
  5. 2105

    Data Sheet 1_Effect of thyme-ivy syrup on antiviral immune response in patients with mild COVID-19: a prospective, open-label, randomized pilot study.docx by Stephanie Dauth (13274397)

    Published 2025
    “…Significant between-group differences were observed for changes in some parameters at day 4 (e.g., IL-10) and day 14. …”
  6. 2106

    Data Sheet 1_Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.docx by Heinz Wiendl (237353)

    Published 2025
    “…IgG and IgM levels remained above the lower limits of normal in most participants. sNfL levels decreased, remaining reduced by M24. Significant reductions in the annualized combined unique active lesion count occurred from M2 onwards. …”
  7. 2107

    Data Sheet 2_Blood biomarker dynamics in people with relapsing multiple sclerosis treated with cladribine tablets: results of the 2-year MAGNIFY-MS study.csv by Heinz Wiendl (237353)

    Published 2025
    “…IgG and IgM levels remained above the lower limits of normal in most participants. sNfL levels decreased, remaining reduced by M24. Significant reductions in the annualized combined unique active lesion count occurred from M2 onwards. …”
  8. 2108

    Table 1_GLP1 receptor agonists and SGLT2 inhibitors for the prevention or delay of type 2 diabetes mellitus onset: a systematic review and meta-analysis.docx by Farah Ghobar (22480732)

    Published 2025
    “…Finally, no significant change in fasting insulin levels was noticed with an overall SMD of -1.74 (95% CI: [-6.84, 3.37]), which was also not statistically significant (p-value: 0.55). …”
  9. 2109

    Supplementary file 3_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

    Published 2025
    “…The expert authority coefficient (Cr) was 0.86, and the coefficient of variation (CV) for item importance scores decreased across rounds (from 0.07–0.16 in Round 1 to 0.07–0.13 in Round 2), indicating high expert consensus. …”
  10. 2110

    Supplementary file 2_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

    Published 2025
    “…The expert authority coefficient (Cr) was 0.86, and the coefficient of variation (CV) for item importance scores decreased across rounds (from 0.07–0.16 in Round 1 to 0.07–0.13 in Round 2), indicating high expert consensus. …”
  11. 2111

    Supplementary file 6_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

    Published 2025
    “…The expert authority coefficient (Cr) was 0.86, and the coefficient of variation (CV) for item importance scores decreased across rounds (from 0.07–0.16 in Round 1 to 0.07–0.13 in Round 2), indicating high expert consensus. …”
  12. 2112

    Supplementary file 1_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

    Published 2025
    “…The expert authority coefficient (Cr) was 0.86, and the coefficient of variation (CV) for item importance scores decreased across rounds (from 0.07–0.16 in Round 1 to 0.07–0.13 in Round 2), indicating high expert consensus. …”
  13. 2113

    Supplementary file 5_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

    Published 2025
    “…The expert authority coefficient (Cr) was 0.86, and the coefficient of variation (CV) for item importance scores decreased across rounds (from 0.07–0.16 in Round 1 to 0.07–0.13 in Round 2), indicating high expert consensus. …”
  14. 2114

    Supplementary file 4_Development and preliminary clinical feasibility of a Delphi-based aerobic exercise prescription for children with asthma.docx by Ying Zhang (40767)

    Published 2025
    “…The expert authority coefficient (Cr) was 0.86, and the coefficient of variation (CV) for item importance scores decreased across rounds (from 0.07–0.16 in Round 1 to 0.07–0.13 in Round 2), indicating high expert consensus. …”
  15. 2115

    Data Sheet 3_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  16. 2116

    Data Sheet 1_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  17. 2117

    Data Sheet 8_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  18. 2118

    Data Sheet 9_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  19. 2119

    Data Sheet 4_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”
  20. 2120

    Data Sheet 7_Sodium-glucose cotransporter-2 inhibitor therapy improves renal and hepatic function in patients with cirrhosis secondary to metabolic dysfunction associated steatotic... by Alessandro Colletta (1509928)

    Published 2025
    “…The SGLT2i group also demonstrated significant improvement in MELD-Na, MELD 3.0 and CTP scores, with greater resolution of hepatic decompensations, proteinuria, as well as better BMI and HbA1c outcomes (all p < 0.01).…”